Selecting patients for long-acting novel antipsychotic therapy

Australasian Psychiatry

Volumn 14, Issue 1, 2006, Pages 38-42

  Lambert, Tim ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ORYGEN RESEARCH CENTRE   (Australia)

Author keywords

Long acting novel antipsychotics; Patient selection; Psychosis; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; LONG ACTING DRUG; NEUROLEPTIC AGENT;

ANTICHOLINERGIC EFFECT; ARTICLE; AUSTRALIA; CLINICAL PRACTICE; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; FAMILY; HUMAN; MENTAL PATIENT; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PATIENT SELECTION; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG RESISTANCE; DRUG TOLERANCE; HUMANS; PATIENT SELECTION; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 33645153325     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1111/j.1440-1665.2006.02243.x     Document Type: Article

References (40)

1. Pantelis C, Lambert TJ. Managing patients with 'treatment-resistant' schizophrenia. Medical Journal of Australia 2003; 178 (Suppl.): S62-S66.
2. Peuskens J. The evolving definition of treatment resistance. Journal of Clinical Psychiatry 1999; 60 (Suppl.): 4-8.
3. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988; 45: 789-796.
4. Doering S, Muller E, Kopcke W et al. Predictors of relapse and rehospitalisation in schizophrenia and schizoaffective disorder. Schizophrenia Bulletin 1998; 24: 87-98.
5. Kane JM, Aguglia E, Altamura AC et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology 1998; 8: 55-66.
6. Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs 1994; 47: 741-773.
7. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. American Journal Psychiatry 1997; 154: 1-63.
8. Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. Journal of Clinical Psychiatry 2003; 64 (Suppl.): 5-19.
9. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatrica Scandinavica, Supplementum 2000; 102: 83-86.
10. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatric Services 1998; 49: 196-201.
11. Dirks JF, Kinsman RA. Nondichotomous patterns of medication usage: The yes-no fallacy. Clinical Pharmacology and Therapeutics 1982; 31: 413-417.
12. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Medical Care 1999; 37: AS81-AS86.
13. Kelly GR, Mamon JA, Scott JE. Utility of the health belief model in examining medication compliance among psychiatric outpatients. Social Science & Medicine 1987; 25: 1205-1211.
14. Davis JM, Kane JM, Marder SR et al. Dose response of prophylactic antipsychotics. Journal of Clinical Psychiatry 1993; 54 (Suppl.): 24-30.
15. Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic out-patients: The seven year follow-up of the Medical Research Council fluphenazine/ placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. British Journal of Psychiatry 1985; 146: 469-474.
16. Sheitman BB, Lieberman JA. The natural history and pathophysiology of treatment resistant schizophrenia. Journal Psychiatric Research 1998; 32: 143-150.
17. Keith SJ, Kane JM, Turner M, Conley RR, Nasrallah HA. Academic highlights: Guidelines for the use of long-acting injectable atypical antipsychotics. Journal of Clinical Psychiatry 2004; 65: 120-131.
18. Moller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. International Clinical Psychopharmacology 2005; 20: 121-130.
19. Lambert TJ, Emmerson B, Hustig H, Rosillon D, Farmer D, Jacobs A, Methven C. On behalf of the e-STAR Study Group (2005). Evaluation of Australian patients from the e-STAR survey considered for initiation on a long acting novel antipsychotic (LANA) - a retrospective analysis. Poster presented at WPA section of Epidemiology and Public Health, Brisbane Australia, 5-7 July.
20. Weiden P, Glazer W. Assessment and treatment selection for 'revolving door' inpatients with schizophrenia. Psychiatric Quarterly 1997; 68: 377-392.
21. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in 'revolving door' schizophrenic patients. Journal of Clinical Psychiatry 1996; 57: 337-345.
22. Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics 2005; 23: 299-314.
23. Lambert TJ, Castle DJ. Pharmacological approaches to the management of schizophrenia. Medical journal of Australia 2003; 178 (Suppl.): S57-S61.
24. Keshavan MS, Rabinowitz J, DeSmedt G, Harvey PD, Schooler N. Correlates of insight in first episode psychosis. Schizophrenia Research 2004; 70: 187-194.
25. Nakano H, Terao T, Iwata N, Hasako R, Nakamura J. Symptomatological and cognitive predictors of insight in chronic schizophrenia. Psychiatry Research 2004; 127: 65-72.
26. Ehret MJ, Fuller MA. Long-acting injectable risperidone. Ann Pharmacother 2004; 38: 2122-2127.
27. Janicak PG. The relevance of clinical pharmacokinetics and therapeutic drug monitoring: Anticonvulsant mood stabilizers and antipsychotics. Journal of Clinical Psychiatry 1993; 54 (Suppl.): 35-41; discussion 55-56.
28. Dencker SJ. The risk/benefit ratio of depot neuroleptics: A Scandinavian perspective. Journal of Clinical Psychiatry 1984; 45: 22-27.
29. Barnes TRE, Curson DA. Long-term depot antipsychotics: A risk-benefit assessment. Drug Safety 1994; 10: 464-479.
30. Gerlach J, Larsen EB. Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatrica Scandinavica, Supplementum 1999; 395: 113-117.
31. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. The American Journal of Psychiatry 2003; 160: 1125-1132.
32. Morgan V, Castle D, Jablensky A. The use of psychopharmacological and other treatments by persons with psychosis. National Survey of Mental Health and Wellbeing 2002; Bulletin 4. National Mental Health Strategy.
33. Lambert TJR, Singh B. Psychotropic prescribing in community mental health clinics. International Journal of Neuropsychopharmacology 2000; 3: S123 (Abstract).
34. Humberstone V, Wheeler A, Lambert T. An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Australian and New Zealand Journal of Psychiatry 2004; 38: 240-245.
35. Meise U, Fleischhacker WW. Perspectives on treatment needs in schizophrenia. British Journal of Psychiatry Supplement 1996; 29: 9-16.
36. Rosillon D, Caleo S, Farmer D, Ingham M, Jacobs A on behalf of the e-STAR study group. The electronic schizophrenia treatment adherence registry e-STAR: Baseline results for Germany, Spain, and Australia. Presented at the ISPOR, 10th Annual Meeting, Washington, 15-18 May 2005.
37. Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. American Journal Hospital Pharmacy 1991; 48: 1978-1988.
38. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin 1997; 23: 637-651.
39. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: Codification and update. Bulletin of the American Academy of Psychiatry & the Law 1986; 14: 105-122.
40. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry 2002; 63: 892-909.